The Global Burden of Disease (GBD) study is a comprehensive epidemiological effort to systematically quantify and study the morbidity and mortality of major diseases by analyzing disease prevalence, risk factors, and outcomes across multiple countries and time periods [1]. Disability-adjusted life years (DALYs) represent total years of life lost to disease and years lived with disability. Many dermatologic diseases are nonfatal but high-burden conditions due to their elevated prevalence and substantial negative quality-of-life impacts; recently, dermatologic conditions became the fourth leading cause of morbidity worldwide [1]. Limited access to specialists, high costs of care, and socioeconomic and geographic disparities compound the burden. Patients’ psychosocial well-being can decline due to the visibility of dermatologic conditions [2].

Thus, examining the lived experiences that patients discuss within online networks such as PatientsLikeMe (PLM) becomes crucial. PLM empowers those with similar conditions to emotionally connect, share information, and build interactive communities. Since 2004, PLM has gained ≥850,000 members reporting ≥2800 health conditions [3], creating a large real-world database of patient-generated information. Given PLM’s popularity, this study and our previous work [4] analyze user demographics and illuminate the daily struggles, treatment challenges, and emotional impact of high-burden dermatologic conditions identified by the GBD. Greater understanding could build awareness of patient concerns, identify trends and unmet needs in disease management, and ultimately contribute to improved patient-centered care and outcomes.

Worldwide age-standardized DALYs and prevalence of skin and subcutaneous diseases stratified by sex were obtained from the GBD 2019 [5], as were 95% uncertainty intervals (UIs), capturing uncertainties associated with systematic errors in myriad primary data sources [6]. Total numbers of PLM users, user-reported age, age at first symptom, sex, and diagnosis status was retrieved for each skin disease in April 2023. Nonparametric Spearman correlations (R version 4.2.2; R Core Team) were used to assess the correlation of GBD prevalence and morbidity with PLM user numbers (statistical significance: 2-tailed P<.05). To explore differences by sex, z tests of proportions were performed for each disease category to compare fractions of men within GBD prevalence values and PLM users who self-reported sex.

All research complied with regulations for the protection of human subjects under 45 CFR 46.104(d) (4), using publicly available data without requiring additional contact or permissions from content creators.

In the GBD, atopic dermatitis had the highest age-standardized DALYs at 96.7 (95% UI 51.5‐162.6) per 100,000 persons. Fungal skin diseases were most prevalent worldwide (n=578.1 million, 95% UI 521.0‐645.6 million) in both sexes, but men had a slightly higher fraction (51.5%) of total prevalence (Table 1). Acne vulgaris was second-most prevalent (n=231.2 million), followed by scabies (n=187.4 million) and atopic dermatitis (n=171.2 million). Alopecia areata demonstrated the greatest sex difference in GBD prevalence. The PLM psoriasis community had the most users (n=6451), followed by acne vulgaris (n=913) and viral skin diseases (combined users: n=889). No PLM users were found in searches for pruritis and decubitus ulcers. However, Spearman rank-based correlation was statistically significant for the number of PLM disease community users and GBD DALYs (P=.04), but not PLM users and GBD prevalence (P=.50). Most PLM users self-identified as women, with men comprising only 17.9% (pyoderma) to 46.9% (seborrheic dermatitis). Except for atopic dermatitis, scabies, and seborrheic dermatitis, sex proportions for GBD prevalence and PLM users differed significantly (z test: P<.05).

Our GBD-specific findings parallel past results [7]. However [4], numbers and patterns differed between PLM users, GBD disease burden, and prevalence. Varied demographics and data sources could limit comparisons and generalizability; PLM data are self-reported, and PLM reflects online health communities and social media in having predominantly English-speaking female users with internet access [8]. Suggested positive correlations between use and women reporting fair or poor health and comorbidities [9] may partially explain disease-specific z test findings. Conversely, the GBD synthesizes census, registry, and other epidemiological data to broadly capture disease prevalence. Our comparative GBD and PLM findings might therefore be biased by disease awareness, diagnostic accuracy, and reporting quality. GBD categories are limited and aggregated (eg, “viral skin diseases”); thus, data from many PLM communities not explicitly delineated by the GBD (eg, lupus, rosacea, cutaneous T cell lymphoma) were combined for comparisons. However, while PLM data do not reflect global burden, our rank-based correlations still suggest potential associations between GBD morbidity and PLM user numbers, highlighting PLM’s potential for complementing epidemiologic data. Future integration of patient-generated data could add nuanced insight into patient experiences and needs, thereby empowering targeted care [10].